For the public record: Critical questions FDA must address about vaccine safety
By Steve Kirsch
On October 26, I was invited by the FDA to give a 3-minute slide presentation during the Open Public Hearing session at the meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) which is the outside committee of the FDA that reviews vaccine safety and efficacy.
Today’s meeting is focused on whether or not to extend the EUA of the Pfizer vaccines for children aged 5 to 11.
Since I was only given 3 minutes of talk time, I prepared just 30 slides at the meeting. All the slides were questions that I believed needed to be fully answered before any vote to authorize vaccination for 5 to 11 year olds. After all, once you’ve been vaccinated, you can never be unvaccinated.
Since I had prepared over 100 questions for the committee, I thought it would be useful for both the VRBPAC committee, as well as the public, to post my slides publicly.